INTRODUCTION
Endometriosis affects an estimated 1 in 10 women during their reproductive years (1). According to the World Bank it is projected that in 2010 there are 1,761,687,000 women in the world aged between 15 and 49 (2). If 10% of these have endometriosis, it equates to more than 176 million women throughout the world during the prime years of their lives. Yet, only a fraction of these will ever have been diagnosed and treated. The disease is defined as the presence of endometriallike tissue outside the uterus, which induces a chronic, inflammatory reaction. The associated pain, infertility and pelvic masses can impact on general physical, mental and social well-being, and symptoms may persist despite seemingly adequate medical and/or surgical treatment of the disease (3). However, we see relatively little investment in finding treatments for endometriosis. Consequently, treatment fai-lures are common. Furthermore, many clinical questions remain unanswered because of a lack of large-scale, multi-centre, clinical trials with sufficient patient numbers to provide results with statistical significance. This primarily occurs because researchers tend to perform small, isolated projects, often with limited local funding, resulting in even well-designed studies producing no definitive results and/or answers ( Fig. 1) . In fact, a common conclusion seen in papers relating to endometriosis is: while these results are encouraging, a larger prospective trial, which is adequately powered, is required to test this hypothesis properly. It has become evident that highly coordinated efforts are necessary to conduct the large, prospective, adequately powered trials that are required to answer important clinical questions. Thus, at the 9 th World Congress on Endometriosis in Maastricht in September 2005, a meeting was held for interested parties to "brainstorm" potential solutions to this challenge.
Creating solutions in endometriosis: global collaboration through the World Endometriosis Research Foundation
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The Global Study of Women's Health (GSWH)
GSWH is the first, prospective epidemiological study to investigate the impact of, and risk-factors for, endometriosis in 16 centres in 10 countries. GSWH has recruited women aged 18 to 45 undergoing laparoscopy across centers in Africa, Europe, North America, South America, and Asia. These women were asked to complete a questionnaire either on paper or online in their own language prior to their surgery. Those found not to have endometriosis at laparoscopy acted as controls. By using standardized data collection in centres across the world and across diverse health care settings, we are gaining insight into the global impact of endometriosis at both a personal and societal level (4).
The Women's Health Symptoms Study (WHSS)
WHSS is the first prospective epidemiological study, at a global level, to investigate the potential of a symptombased questionnaire to predict the diagnosis of endometriosis. The WHSS has prospectively recruited women aged 18 to 45 having a first laparoscopy across centres in Africa, Europe, North America, South America, and Asia. The women were asked to complete a questionnaire either on paper or online in their own language prior to their surgery. Those found not to have endometriosis at laparoscopy act as controls. Using standardized data collection in centres across the world and across diverse health care settings will maximize the opportunity to develop a validated, symptombased, diagnostic tool (4). A study of this scale, involving to date 1,884 women from 19 centres in 13 countries, has never been undertaken before.
EndoCost
The aim of the EndoCost study is to calculate the costs of endometriosis from a societal perspective; again, a study like this has never before been undertaken in the field of endometriosis. A prospective, prevalence-based cost-ofillness study has been initiated to collect cost data. This approach has been combined with a retrospective assessment of endometriosis-related cost and impact on quality of life in all participating women. The study, which involves 12 centres in ten countries, will calculate the level of endometriosis costs, elicit the most the initiative was, and is, supported by the American Society for Reproductive Medicine (ASRM), the European Society of Human Reproduction and Embryology (ESHRE), and the World Endometriosis Society (WES). The Society for Gynecological Investigation (SGI) has since lent its support as well. By creating a global platform, it has now become possible to pool resources and work together across borders to achieve statistically meaningful results (Fig. 2) . 
WERF's mission
Delivering answers
In a world where benign (female) diseases are not typically prioritized, the challenge remains to justify investment for research into the pathogenesis of, and improved treatments for, endometriosis. Thus, justification for funding needs to be developed, and WERF took on this challenge as its first priority by raising funding for, and conducting, three prospective studies that had never been undertaken in the field of endometriosis on such a large scale.
WERF is committed to providing the global platform for this collaboration. WERF wants to work with those who wish to contribute to finding solutions for the more than 176 million women whose lives can be compromised by this disease. Our chances for success will be dramatically increased if we pool our resources and intelligence, and work together.
